Introduction/Background Pelvic exenteration (PE) is indicated in cases of unresponsive, recurrent pelvic cancer or for palliative intent. Despite the fact that the surgery is associated with a high rate of morbidity, it is currently the only real option that can effect a cure.
Methodology Patients who underwent PE between January 2011 and April 2019 in our centre were retrospectively reviewed. Data related to surgery, complications and outcomes were recorded.
Results Thirty-five patients were included. PE was performed due to recurrent gynaecological cancer, persistence of disease and after first diagnosis in 29 (82,9%), 4 (11,4%) and 2 (5,7%) patients, respectively. Total PE was performed in 23 cases (65,7%), followed by anterior PE in 7 cases (20%) and posterior PE in 5 cases (14,3%). Early grade II, III, IV and V complications occurred in 21 (60%), 9 (25,7%), 4 (11,4%) and 1 (2,9%) patients, respectively. One patient died within the first 30 postoperative days due to surgery-related complications. Medium-late grade II, III, IV and V complications occurred in 20 (57,1%), 16 (45,7%), 5 (14,3%) and 3 cases (8,6%), respectively. Three patients died after > 30-day period from surgery-related complications. The overall survival (OS) and disease-free survival (DFS) at 48 months after PE was 39.8% and 28.7% respectivel.
Conclusion PE provides about a 40% 4-year survival chance in a selected group of patients. The early-complications rate and 30-day mortality were acceptable. Nevertheless, the medium-late complication grades II-V were 57, 46, 14 and 9%, respectively. We must focus on identifying those patients who could potentially benefit most from P.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.